Amgen (AMGN) Other financing activities (2009 - 2026)
Amgen (AMGN) posted quarterly Other financing activities of -$104.0 million for Q1 2026, down 285.19% year-over-year from $56.2 million in Q1 2025, and down 282.46% quarter-over-quarter from $57.0 million in Q4 2025.
Amgen (AMGN) Other financing activities (2009 - 2026) Analysis & Trends
Amgen's Other financing activities history runs 18 years deep, the most recent figure standing at -$104.0 million for Q1 2026.
- In Q1 2026, Other financing activities fell 285.19% year-over-year to -$104.0 million; the TTM figure through Mar 2026 stood at -$129.0 million (down 111.48% YoY), while the FY2025 annual figure was -$52.0 million, up 58.06% from the prior year.
- Other financing activities for Q1 2026 stood at -$104.0 million, down from $57.0 million in the prior quarter.
- The five-year high for Other financing activities was $57.0 million in Q4 2025, with the low at -$104.0 million in Q1 2026.
- The 5-year median for Other financing activities is -$26.0 million (2022), against an average of -$26.8 million.
- The sharpest annual moves came in 2025 and 2026: Other financing activities jumped 2950.0% in 2025, then slumped 285.19% in 2026.
- Amgen's Other financing activities stood at $10.0 million in 2022, then slumped by 150.0% to -$5.0 million in 2023, then soared by 60.0% to -$2.0 million in 2024, then surged by 2950.0% to $57.0 million in 2025, then tumbled by 282.46% to -$104.0 million in 2026.
- Business Quant data shows AMGN's Other financing activities at -$104.0 million in Q1 2026, $57.0 million in Q4 2025, and $10.0 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Johnson & Johnson | 652.20 Bn | 631.44 Bn | 17.26 Bn |
| 2 | AbbVie | 469.51 Bn | 462.94 Bn | 12.70 Bn |
| 3 | Merck | 376.81 Bn | 369.67 Bn | 12.21 Bn |
| 4 | Novartis Ag | 303.04 Bn | 295.35 Bn | 11.24 Bn |
| 5 | Astrazeneca | 257.61 Bn | 252.71 Bn | 12.86 Bn |
| 6 | Amgen | 237.37 Bn | 223.38 Bn | 7.24 Bn |
| 7 | Gilead Sciences | 181.73 Bn | 178.55 Bn | 6.22 Bn |
| 8 | Pfizer | 159.66 Bn | 147.96 Bn | 10.94 Bn |
| 9 | Gsk | 106.24 Bn | 102.07 Bn | 8.24 Bn |
| 10 | Sanofi | 55.07 Bn | 47.69 Bn | 10.79 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -120.00 Mn |
| Jun 30, 2026 | -120.00 Mn |
| Mar 31, 2026 | -104.00 Mn |
| Mar 31, 2026 | -104.00 Mn |
| Dec 31, 2025 | 57.00 Mn |
| Dec 31, 2025 | 57.00 Mn |
| Sep 30, 2025 | 10.00 Mn |
| Sep 30, 2025 | 10.00 Mn |
| Jun 30, 2025 | -92.00 Mn |
| Jun 30, 2025 | -92.00 Mn |
| Mar 31, 2025 | -27.00 Mn |
| Mar 31, 2025 | -27.00 Mn |
| Dec 31, 2024 | -2.00 Mn |
| Dec 31, 2024 | -2.00 Mn |
| Sep 30, 2024 | 8.00 Mn |
| Sep 30, 2024 | 8.00 Mn |
| Jun 30, 2024 | -40.00 Mn |
| Jun 30, 2024 | -40.00 Mn |
| Mar 31, 2024 | -90.00 Mn |
| Mar 31, 2024 | -90.00 Mn |